{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:19:11Z","timestamp":1790867951312,"version":"4.1.0"},"reference-count":46,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2002,5]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To review preclinical and clinical information on flavopiridol, an inhibitor of cyclin-dependent kinases (CDKs), tested as an antitumor agent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>Primary and review articles were identified by MEDLINE search (1990\u2013June 2001). Abstracts from recent meetings were also used as source materials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA EXTRACTION:<\/jats:title>\n                    <jats:p>Flavopiridol was reviewed with regard to its mechanisms, preclinical and clinical results, pharmacokinetics, and metabolism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS:<\/jats:title>\n                    <jats:p>Flavopiridol is an inhibitor of several CDKs and displays unique anticancer properties. In addition to direct CDK inhibition, flavopiridol also exhibited other features such as inducing apoptosis in many cancer cell lines, decreasing cyclin D1 concentration, and inhibiting angiogenesis. Preclinical xenograft models showed significant antitumor activity for flavopiridol. The regimen using 72-hour continuous infusion every 2 weeks has been most extensively applied in clinical trials, with a 1-hour infusion currently being explored to achieve higher peak concentrations. Several Phase I and II trials have been reported, with some evidence of antitumor activity noted. Further Phase I and II trials using flavopiridol as a single agent and in combination with standard chemotherapeutic regimens and various tumor types are ongoing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Flavopiridol is the first CDK inhibitor to enter clinical trials. Several Phase I and Phase II clinical trials with different regimens (72-h or 1-h infusion) have been completed. Initial clinical trials have been intriguing, but many questions remain: What is the best regimen (\u226472-h infusion)? Does optimal future development of this drug depend on the combination with other chemotherapy? What is the best combination of flavopiridol with other chemotherapy?<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1a162","type":"journal-article","created":{"date-parts":[[2003,6,4]],"date-time":"2003-06-04T16:20:48Z","timestamp":1054743648000},"page":"905-911","source":"Crossref","is-referenced-by-count":105,"title":["Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Clinical Development"],"prefix":"10.1177","volume":"36","author":[{"given":"Suoping","family":"Zhai","sequence":"first","affiliation":[{"name":"Suoping Zhai MD PhD, Clinical Pharmacology Research Core, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian M","family":"Senderowicz","sequence":"additional","affiliation":[{"name":"Adrian M Senderowicz MD, Oral Pharyngeal Cancer Branch, National Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A","family":"Sausville","sequence":"additional","affiliation":[{"name":"Edward A Sausville MD PhD, Developmental Therapeutics Program, National Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D","family":"Figg","sequence":"additional","affiliation":[{"name":"William D Figg PharmD, Molecular Pharmacology Section and Clinical Pharmacology Research Core, Center for Cancer Research, National Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2002,5,1]]},"reference":[{"key":"bibr-bibr1-aph.1A162","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5293.1672"},{"key":"bibr-bibr2-aph.1A162","doi-asserted-by":"publisher","DOI":"10.1038\/374131a0"},{"key":"bibr-bibr3-aph.1A162","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cellbio.13.1.261"},{"key":"bibr-bibr4-aph.1A162","volume-title":"Principles of molecular medicine","author":"Nguyen LQ","year":"1988"},{"key":"bibr-bibr5-aph.1A162","doi-asserted-by":"publisher","DOI":"10.1126\/science.7997877"},{"key":"bibr-bibr6-aph.1A162","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-437X(96)90011-8"},{"key":"bibr-bibr7-aph.1A162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.9.2986"},{"key":"bibr-bibr8-aph.1A162","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(98)00062-X"},{"key":"bibr-bibr9-aph.1A162","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.5.376"},{"key":"bibr-bibr10-aph.1A162","first-page":"2973","volume":"56","author":"Carlson BA","year":"1996","journal-title":"Cancer Res"},{"key":"bibr-bibr11-aph.1A162","first-page":"4634","volume":"59","author":"Carlson B","year":"1999","journal-title":"Cancer Res"},{"key":"bibr-bibr12-aph.1A162","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1994.1742"},{"key":"bibr-bibr13-aph.1A162","first-page":"424","volume":"37","author":"Carlson B","year":"1996","journal-title":"Proc Am Assoc Cancer Res"},{"key":"bibr-bibr14-aph.1A162","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.7.2735"},{"key":"bibr-bibr15-aph.1A162","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(93)90590-S"},{"key":"bibr-bibr16-aph.1A162","first-page":"3375","volume":"57","author":"Bible KC","year":"1997","journal-title":"Cancer Res"},{"key":"bibr-bibr17-aph.1A162","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.2.458"},{"key":"bibr-bibr18-aph.1A162","doi-asserted-by":"publisher","DOI":"10.1172\/JCI3661"},{"key":"bibr-bibr19-aph.1A162","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.393"},{"key":"bibr-bibr20-aph.1A162","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M005267200"},{"key":"bibr-bibr21-aph.1A162","first-page":"2419","volume":"60","author":"Bible KC","year":"2000","journal-title":"Cancer Res"},{"key":"bibr-bibr22-aph.1A162","first-page":"975","volume":"55","author":"Michalides R","year":"1995","journal-title":"Cancer Res"},{"key":"bibr-bibr23-aph.1A162","first-page":"1634","volume":"57","author":"Gansauge S","year":"1997","journal-title":"Cancer Res"},{"key":"bibr-bibr24-aph.1A162","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.12.6380"},{"key":"bibr-bibr25-aph.1A162","first-page":"5433","volume":"59","author":"Melillo G","year":"1999","journal-title":"Cancer Res"},{"key":"bibr-bibr26-aph.1A162","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980703)77:1<146::AID-IJC22>3.0.CO;2-B"},{"key":"bibr-bibr27-aph.1A162","first-page":"31","volume":"6","author":"Czech J","year":"1995","journal-title":"Int J Oncol"},{"key":"bibr-bibr28-aph.1A162","first-page":"273","volume":"3","author":"Drees M","year":"1997","journal-title":"Clin Cancer Res"},{"key":"bibr-bibr29-aph.1A162","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/84.22.1736"},{"key":"bibr-bibr30-aph.1A162","first-page":"2482","volume":"91","author":"Arguello F","year":"1998","journal-title":"Blood"},{"key":"bibr-bibr31-aph.1A162","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(98)00152-0"},{"key":"bibr-bibr32-aph.1A162","first-page":"149","volume":"63","author":"Ramirez J","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"bibr-bibr33-aph.1A162","first-page":"407","volume":"29","author":"Hagenauer B","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"bibr-bibr34-aph.1A162","first-page":"222","volume":"38","author":"Thomas J","year":"1997","journal-title":"Proc Am Assoc Cancer Res, San Diego"},{"key":"bibr-bibr35-aph.1A162","first-page":"209","volume":"17","author":"Thomas J","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"bibr-bibr36-aph.1A162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.7.1985"},{"key":"bibr-bibr37-aph.1A162","unstructured":"Zhai S, Figg WD, Headlee D, Messmann RA, Arbuck SG, Murgo A,  Pharmacokinetics of flavopiridol 1 hour infusion in patients with refractory neoplasms (abstract). Presented at: the 11th NCI-EORTC-AACR Symposium, Amsterdam, Holland, November 2000."},{"key":"bibr-bibr38-aph.1A162","first-page":"3400","volume":"6","author":"Innocenti F","year":"2000","journal-title":"Clin Cancer Res"},{"key":"bibr-bibr39-aph.1A162","first-page":"343","volume":"7","author":"Kahn ME","year":"2001","journal-title":"Clin Cancer Res"},{"key":"bibr-bibr40-aph.1A162","unstructured":"Senderowicz AM, Messmann R, Arbuck S, Headlee D, Zhai S, Murgo A,  A Phase I clinical trial of 1-hour infusion of flavopiridol, a novel cyclin-depedent kinase inhibitor, in patients with advanced neoplasms (abstract). Proc Am Soc Clin Oncol, New Orleans, 2000."},{"key":"bibr-bibr41-aph.1A162","first-page":"188","volume":"17","author":"Schwartz GK","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"bibr-bibr42-aph.1A162","unstructured":"Tan AR, Zhai S, Kang M, Figg WD, Swain SM. Phase I trial of docetaxel and flavopiridol in metastatic breast cancer: preliminary results (abstract). Presented at: National Cancer Institute, Clinical-Cancer-Research Fellow Symposium, Bethesda, MD, June 12, 2001."},{"key":"bibr-bibr43-aph.1A162","volume-title":"CTEP drug development meeting","year":"2001"},{"key":"bibr-bibr44-aph.1A162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.371"},{"key":"bibr-bibr45-aph.1A162","first-page":"1590","volume":"7","author":"Shapiro GI","year":"2001","journal-title":"Clin Cancer Res"},{"key":"bibr-bibr46-aph.1A162","first-page":"A2","volume":"19","author":"Schiller JH","year":"2000","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1A162","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1A162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:05:36Z","timestamp":1777374336000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1A162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":46,"aliases":["10.1345\/1542-6270(2002)036<0905:fancdk>2.0.co;2"],"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["10.1345\/aph.1A162"],"URL":"https:\/\/doi.org\/10.1345\/aph.1a162","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5]]}}}